The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Sarcoma
FollowWhat is new in Sarcoma research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 3-Dimensional Conformal Radiation TherapyPhase 3 · NCT07615049
- AL3818Phase 3 · NCT03016819 · NCT04165330 · NCT07811297
- AL3818 or placeboPhase 3 · NCT03016819
- At the discretion of the investigatorPhase 3 · NCT03805022
- Biopsy ProcedurePhase 3 · NCT04704661 · NCT05711615 · NCT04458922 · NCT03155620 · NCT05304585 · NCT04577755 · NCT06498648 · NCT07227571 · NCT05333458 · NCT02298959 · NCT03367741 · NCT05836571 · NCT05691504 · NCT04595747 · NCT02923778 · NCT07686367
- Biospecimen CollectionPhase 3 · NCT07261657 · NCT04704661 · NCT05711615 · NCT03141684 · NCT05286801 · NCT07830667 · NCT04458922 · NCT03155620 · NCT04214067 · NCT03660826 · NCT04577755 · NCT06422806 · NCT06498648 · NCT04851119 · NCT07227571 · NCT07539454 · NCT02834013 · NCT03213704 · NCT05333458 · NCT06528769 · NCT04339738 · NCT07466316 · NCT04616560 · NCT02298959 · NCT06571734 · NCT04994132 · NCT05269381 · NCT03367741 · NCT04514484 · NCT05694871 · NCT07615049 · NCT06712810 · NCT07823491 · NCT05836571 · NCT03210714 · NCT05691504 · NCT05235165 · NCT04797767 · NCT03213652 · NCT06327477 · NCT04595747 · NCT02923778 · NCT07576725 · NCT05646316 · NCT07686367
- Bone Marrow AspirationPhase 3 · NCT07466316 · NCT04994132 · NCT06712810 · NCT04797767
- Bone Marrow BiopsyPhase 3 · NCT03660826 · NCT07466316 · NCT04994132 · NCT06712810 · NCT04797767
- Bone ScanPhase 3 · NCT03155620 · NCT05304585 · NCT03213704 · NCT07466316 · NCT04994132 · NCT03210714 · NCT03213652
- BrachytherapyPhase 3 · NCT04214067 · NCT06524778
- BusulfanPhase 3 · NCT02724163
- CalderasibPhase 3 · NCT06345729
- CarboplatinPhase 3 · NCT04999761 · NCT07458347 · NCT06008093 · NCT00077285 · NCT03914612 · NCT03715933
- CisplatinPhase 3 · NCT04999761 · NCT04521686 · NCT07477457 · NCT06008093 · NCT07321912 · NCT00470223 · NCT03965234
- Computed TomographyPhase 3 · NCT07261657 · NCT02713269 · NCT04704661 · NCT05711615 · NCT03141684 · NCT05286801 · NCT04458922 · NCT03155620 · NCT04457258 · NCT04214067 · NCT05304585 · NCT03660826 · NCT04577755 · NCT06498648 · NCT07227571 · NCT07539454 · NCT02834013 · NCT03213704 · NCT05333458 · NCT06528769 · NCT06025747 · NCT04339738 · NCT07466316 · NCT04616560 · NCT05672108 · NCT02298959 · NCT04320888 · NCT04751409 · NCT06571734 · NCT04994132 · NCT05269381 · NCT03367741 · NCT04514484 · NCT05694871 · NCT07615049 · NCT06712810 · NCT07823491 · NCT05836571 · NCT03210714 · NCT05691504 · NCT05235165 · NCT03914612 · NCT03213652 · NCT06327477 · NCT07118176 · NCT04595747 · NCT07576725 · NCT07686367
- conventional surgeryPhase 3 · NCT00077285 · NCT00470223
- CyclophosphamidePhase 3 · NCT04625907 · NCT04897321 · NCT07613723 · NCT07174427 · NCT01864109 · NCT01953900 · NCT01871766 · NCT02574728 · NCT05304585 · NCT02650986 · NCT04388839 · NCT02790515 · NCT07297667 · NCT06023641 · NCT05296564 · NCT07227571 · NCT01804634 · NCT02306161 · NCT03967223 · NCT07222735 · NCT07466316 · NCT05492682 · NCT07428993 · NCT05621668 · NCT06474676 · NCT04994132 · NCT05269381 · NCT06865664 · NCT02869217 · NCT02567435 · NCT00077285 · NCT07321912 · NCT00902044 · NCT06083883 · NCT03449108 · NCT07342738 · NCT03721068 · NCT07194044 · NCT02724163
- CytarabinePhase 3 · NCT03589729 · NCT05735184 · NCT04797767 · NCT02724163
- DacarbazinePhase 3 · NCT03016819 · NCT06835049 · NCT04733183
- DactinomycinPhase 3 · NCT01871766 · NCT05304585 · NCT06023641 · NCT07466316 · NCT04994132 · NCT02567435
- Diagnostic Imaging TestingPhase 3 · NCT06422806 · NCT05646316
- Digoxin (0.25mg)Phase 3 · NCT03016819
- DivarasibPhase 3 · NCT07541170
- DocetaxelPhase 3 · NCT03598595 · NCT06498648 · NCT04140526 · NCT01933932 · NCT04577014
- DoxorubicinPhase 3 · NCT06088290 · NCT04625907 · NCT05824975 · NCT02811523 · NCT01864109 · NCT05099666 · NCT01871766 · NCT07802652 · NCT06422806 · NCT06835049 · NCT06239272 · NCT05809830 · NCT06840886 · NCT04968106 · NCT02306161 · NCT07477457 · NCT07125183 · NCT07823491 · NCT07321912 · NCT04874311 · NCT04776525 · NCT07460986 · NCT05774275 · NCT06277154 · NCT04028063 · NCT07194044 · NCT01746238 · NCT03805022
- Doxorubicin HydrochloridePhase 3 · NCT02306161 · NCT07049848 · NCT00077285 · NCT00470223
- Echocardiography TestPhase 3 · NCT04704661 · NCT05711615 · NCT05286801 · NCT03660826 · NCT06422806 · NCT07227571 · NCT02834013 · NCT05333458 · NCT04616560 · NCT05691504
- eribulinPhase 3 · NCT05824975 · NCT07811232 · NCT06957431 · NCT06263231
- ErsodetugPhase 3 · NCT06881992
- EtoposidePhase 3 · NCT01864109 · NCT05590572 · NCT01871766 · NCT02574728 · NCT02306161 · NCT00077285 · NCT07321912 · NCT00470223 · NCT07194044
- Etoposide PhosphatePhase 3 · NCT01871766 · NCT02306161
- Excisional BiopsyPhase 3 · NCT05646316
- Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cyclesPhase 3 · NCT07871864
- External Beam Radiation TherapyPhase 3 · NCT04214067 · NCT02306161
- FludarabinePhase 3 · NCT04897321 · NCT07613723 · NCT07174427 · NCT01953900 · NCT02790515 · NCT07297667 · NCT07227571 · NCT01804634 · NCT03967223 · NCT07222735 · NCT07428993 · NCT06865664 · NCT02869217 · NCT00902044 · NCT03449108 · NCT07342738 · NCT03721068 · NCT02724163
- GanitumabPhase 3 · NCT02306161
- Gemtuzumab OzogamicinPhase 3 · NCT03589729 · NCT02724163
- IfosfamidePhase 3 · NCT04625907 · NCT01864109 · NCT01871766 · NCT06835049 · NCT06239272 · NCT04968106 · NCT02306161 · NCT07477457 · NCT07823491 · NCT00077285 · NCT07321912 · NCT04776525 · NCT00470223 · NCT06277154 · NCT07194044
- Ifosfamide or dacarbazinePhase 3 · NCT03805022
- IGIMRT 27 Gy in 3 fractionsPhase 3 · NCT01223248
- IGIMRT using a single dose of 24 GyPhase 3 · NCT01223248
- ImatinibPhase 3 · NCT02413736
- Indocyanine Green SolutionPhase 3 · NCT05646316
- INT230-6Phase 3 · NCT06263231
- Intensity-Modulated Radiation TherapyPhase 3 · NCT03361436 · NCT07615049 · NCT07823491 · NCT06327477
- ION363Phase 3 · NCT04768972
- Irinotecan HydrochloridePhase 3 · NCT07466316 · NCT02567435 · NCT00077285
- Liposomal daunorubicinPhase 3 · NCT02724163
- Lumbar PuncturePhase 3 · NCT07466316
- LurbinectedinPhase 3 · NCT06088290 · NCT07328425 · NCT05099666 · NCT05734066 · NCT05918640
- Lymph Node BiopsyPhase 3 · NCT07466316
- Magnetic Resonance ElastographyPhase 3 · NCT05304585 · NCT02298959
- Magnetic Resonance ImagingPhase 3 · NCT07261657 · NCT05711615 · NCT05286801 · NCT03155620 · NCT04214067 · NCT07227571 · NCT02834013 · NCT03213704 · NCT06528769 · NCT06025747 · NCT04339738 · NCT07466316 · NCT04616560 · NCT04320888 · NCT04994132 · NCT05269381 · NCT03367741 · NCT04514484 · NCT05694871 · NCT07615049 · NCT06712810 · NCT07823491 · NCT05836571 · NCT03210714 · NCT05691504 · NCT03213652 · NCT04595747 · NCT02923778 · NCT07576725 · NCT07686367
- MethotrexatePhase 3 · NCT07477457 · NCT07321912 · NCT00470223
- Midazolam 2 mg for CYP3A4 phenotypingPhase 3 · NCT03016819
- Minimally Invasive SurgeryPhase 3 · NCT05646316
- MitoxantronePhase 3 · NCT04797767 · NCT02724163
- Multigated Acquisition ScanPhase 3 · NCT04704661 · NCT05711615 · NCT03660826 · NCT06422806 · NCT07227571 · NCT04616560 · NCT06571734 · NCT07823491 · NCT05691504
- NivolumabPhase 3 · NCT04416568 · NCT04551430 · NCT04902443 · NCT04624178 · NCT03465592 · NCT03138161 · NCT02834013 · NCT04420975 · NCT03307616 · NCT04339738 · NCT04803877 · NCT03367741 · NCT04514484 · NCT05836571 · NCT05407441 · NCT06638931 · NCT07444619 · NCT03449108 · NCT07576725 · NCT03282344 · NCT03628209 · NCT07541170
- paclitaxelPhase 3 · NCT05824975 · NCT06840886 · NCT05039801 · NCT04339738 · NCT03914612 · NCT05411237
- PazopanibPhase 3 · NCT06239272 · NCT05180695 · NCT07444619 · NCT06816771 · NCT02203760 · NCT06263231
- Pegylated G-CSFPhase 3 · NCT01933932
- Pegylated liposomal doxorubicinPhase 3 · NCT06981637 · NCT05411237 · NCT05774275
- Pelvic LymphadenectomyPhase 3 · NCT05646316
- PembrolizumabPhase 3 · NCT03414229 · NCT05824975 · NCT07252739 · NCT07458347 · NCT06789172 · NCT07905924 · NCT04214067 · NCT07007273 · NCT06422806 · NCT07283731 · NCT07223047 · NCT04140526 · NCT07089992 · NCT04483778 · NCT06898970 · NCT03069378 · NCT06113809 · NCT04784247 · NCT06345729 · NCT05492682 · NCT05488366 · NCT03092323 · NCT02298959 · NCT02432963 · NCT05269381 · NCT04541108 · NCT05732831 · NCT04616248 · NCT07823491 · NCT04185883 · NCT06008093 · NCT03914612 · NCT05961761 · NCT05859074 · NCT04332874 · NCT07695311 · NCT07541170
- Positron Emission TomographyPhase 3 · NCT04704661 · NCT05286801 · NCT03155620 · NCT04457258 · NCT05304585 · NCT07227571 · NCT07466316 · NCT04320888 · NCT04994132 · NCT06712810 · NCT03210714 · NCT03213652 · NCT07118176 · NCT04595747
- Postoperative intensity modulated radiation therapyPhase 3 · NCT02565498
- Preoperative chemotherapyPhase 3 · NCT04031677
- Preoperative intensity modulated radiation therapyPhase 3 · NCT02565498
- Radiation TherapyPhase 3 · NCT00508443 · NCT05304585 · NCT07222735 · NCT06812052 · NCT04420975 · NCT03307616 · NCT06025747 · NCT07466316 · NCT05488366 · NCT04994132 · NCT04616248 · NCT02567435 · NCT00077285 · NCT02923778 · NCT01746238
- ResectionPhase 3 · NCT07650656 · NCT04506008 · NCT04562480 · NCT07466316 · NCT06327477
- Rosuvastatin 10 mg tablet.Phase 3 · NCT03016819
- SelumetinibPhase 3 · NCT06735820 · NCT01933932
- Sentinel Lymph Node MappingPhase 3 · NCT05646316
- Short course vaginal cuff brachytherapyPhase 3 · NCT03422198
- Sodium Chloride solution 0.9%Phase 3 · NCT05328258
- Stereotactic RadiosurgeryPhase 3 · NCT02713269 · NCT02306161
- SurgeryPhase 3 · NCT04031677 · NCT01864109 · NCT06835049 · NCT07612098 · NCT06660810
- Surgical ProcedurePhase 3 · NCT07615049 · NCT07823491
- TBI-1301Phase 3 · NCT07174427 · NCT02869217
- TemsirolimusPhase 3 · NCT02567435
- Therapeutic Surgical ProcedurePhase 3 · NCT02306161 · NCT06025747
- ThoracoscopyPhase 3 · NCT05235165
- ThoracotomyPhase 3 · NCT05235165
- TislelizumabPhase 3 · NCT04802876 · NCT05238883 · NCT06332274 · NCT07746141
- TrabectedinPhase 3 · NCT04383119 · NCT02275286 · NCT03138161 · NCT05597917 · NCT04305548 · NCT07444619 · NCT04535271 · NCT06263231
- Transthoracic Echocardiography TestPhase 3 · NCT07823491
- Triptorelin EmbonatePhase 3 · NCT05328258
- tTF-NGRPhase 3 · NCT05597917
- VAC，VAC/VII，CAV/IEPhase 3 · NCT06836492
- Vaginal Cuff BrachytherapyPhase 3 · NCT03422198
- VincristinePhase 3 · NCT04625907 · NCT01864109 · NCT06709495 · NCT01871766 · NCT04796012 · NCT05304585 · NCT04388839 · NCT06023641 · NCT06721689 · NCT02306161 · NCT06541262 · NCT07321912 · NCT07194044
- Vincristine SulfatePhase 3 · NCT02306161 · NCT07466316 · NCT04994132 · NCT02567435 · NCT00077285
- VinorelbinePhase 3 · NCT04625907 · NCT04388839 · NCT06023641 · NCT02567435 · NCT04299113
- Vinorelbine TartratePhase 3 · NCT07466316 · NCT04994132
- X-Ray ImagingPhase 3 · NCT07261657 · NCT05286801 · NCT03155620 · NCT04214067 · NCT04577755 · NCT04851119 · NCT03213704 · NCT04320888 · NCT04994132 · NCT03210714 · NCT03213652
- Zoledronic AcidPhase 3 · NCT03173976 · NCT06625190 · NCT00470223
- CapmatinibPhase 2/3 · NCT06988475
- [18F]FAPI-74Phase 2 · NCT06503146
- [18F]FDGPhase 2 · NCT06503146
- ^1^1C-methioninePhase 2 · NCT01871766
- 131 I-omburtamabPhase 2 · NCT04022213
- 2 cycles of atezolizumab followed by surgery then post-operative radiotherapyPhase 2 · NCT03474094
- 9-ING-41Phase 2 · NCT03678883
- AbemaciclibPhase 2 · NCT02846987 · NCT04040205 · NCT06498648 · NCT06025747 · NCT04941274 · NCT05440786
- ABSK043 single agentPhase 2 · NCT07014137
- ABT-888Phase 2 · NCT01042379
- Actinomycin DPhase 2 · NCT04625907 · NCT04388839
- AdAPT-001Phase 2 · NCT04673942
- Administration of L-TCPhase 2 · NCT06476704
- AdriamycinPhase 2 · NCT06367075
- afamitresgene autoleucel (previously ADP-A2M4)Phase 2 · NCT04044768
- AG-120Phase 2 · NCT04278781
- Albumin-paclitaxel InjectionPhase 2 · NCT06684327
- AldesleukinPhase 2 · NCT05296564 · NCT03449108
- all-trans retinoic acidPhase 2 · NCT06528769
- AmcenestrantPhase 2 · NCT01042379
- Amcenestrant + AbemaciclibPhase 2 · NCT01042379
- Amcenestrant + LetrozolePhase 2 · NCT01042379
- AMG 386 and TrastuzumabPhase 2 · NCT01042379
- AMG 386 with or without TrastuzumabPhase 2 · NCT01042379
- AMG 479 (Ganitumab) plus MetforminPhase 2 · NCT01042379
- AnlotinibPhase 2 · NCT07646080 · NCT06699576 · NCT07612098
- Anlotinib and bempegaldesleukinPhase 2 · NCT07156643
- Anlotinib hydrochloridePhase 2 · NCT05167994
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106CPhase 2 · NCT07686367
- Anti-thymocyte globulin (rabbit)Phase 2 · NCT02790515
- ApatinibPhase 2 · NCT06694324
- Apatinib monotherapyPhase 2 · NCT04072042
- ApheresisPhase 2 · NCT07428993
- Aromatase InhibitorsPhase 2 · NCT03624244
- ARV-471Phase 2 · NCT01042379
- ARV-471 + AbemaciclibPhase 2 · NCT01042379
- ARV-471 + LetrozolePhase 2 · NCT01042379
- ARX788Phase 2 · NCT01042379
- ARX788 + CemiplimabPhase 2 · NCT01042379
- Association of pembrolizumab + cabozantinibPhase 2 · NCT05182164
- ASTX727Phase 2 · NCT04872543
- AtezolizumabPhase 2 · NCT06066138 · NCT03548428 · NCT03141684 · NCT05286801 · NCT04458922 · NCT04796012 · NCT05000294 · NCT05542407 · NCT04273061 · NCT05333458 · NCT07049848 · NCT05019703 · NCT04185883 · NCT06492954
- ATRA+VACPhase 2 · NCT07355855
- ATRA+VAC+AnlotinibPhase 2 · NCT07355855
- Autologous DC vaccinePhase 2 · NCT04166006
- Autologous Tumor Infiltrating Lymphocytes LN-145Phase 2 · NCT03449108
- Autologous Tumor Infiltrating Lymphocytes LN-145-S1Phase 2 · NCT03449108
- AvapritinibPhase 2 · NCT04771520
- avutometinib capsule + defactinib tabletPhase 2 · NCT07743554
- BalstilimabPhase 2 · NCT03860272 · NCT04028063
- BAY2927088Phase 2 · NCT06760819
- Benmelstobart injection combined with Anlotinib hydrochloride capsulePhase 2 · NCT07548177
- Bev + Gem + DocPhase 2 · NCT07547592
- bevacizumabPhase 2 · NCT05824975 · NCT03141684 · NCT04999761 · NCT01871766 · NCT05039801 · NCT03715933 · NCT01746238
- Bezuclastinib in combination with sunitinibPhase 2 · NCT06208748
- Bintrafusp alfaPhase 2 · NCT04874311
- BiopsyPhase 2 · NCT07477457 · NCT05269381 · NCT06327477
- biopsy tract non-resectionPhase 2 · NCT07575724
- biopsy tract resectionPhase 2 · NCT07575724
- BlinatumomabPhase 2 · NCT02790515
- Bone Marrow AspiratePhase 2 · NCT03660826
- Bone Marrow Aspiration and BiopsyPhase 2 · NCT03155620 · NCT03213704 · NCT03210714 · NCT03213652
- BotensilimabPhase 2 · NCT03860272 · NCT04028063
- Bronchoscopy & MetastasectomyPhase 2 · NCT06815666
- CabozantinibPhase 2 · NCT04551430 · NCT04200443 · NCT06156410 · NCT05135975 · NCT05019703 · NCT05836571 · NCT02867592 · NCT07194044
- Cabozantinib S-malatePhase 2 · NCT02243605 · NCT04339738 · NCT03367741 · NCT04514484 · NCT02867592
- CadonilimabPhase 2 · NCT06367075
- CamrelizumabPhase 2 · NCT06694324
- Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)Phase 2 · NCT06074692
- CandonilimabPhase 2 · NCT05926700
- CapivasertibPhase 2 · NCT03660826 · NCT05039801
- Carboplatin.Phase 2 · NCT03678883
- CAV/IE alternate chemotherapyPhase 2 · NCT04589741
- CediranibPhase 2 · NCT03851614
- Cediranib MaleatePhase 2 · NCT03660826
- CelecoxibPhase 2 · NCT02574728
- CemiplimabPhase 2 · NCT06528769 · NCT06444880 · NCT05694871 · NCT01042379
- Cemiplimab plus REGN3767Phase 2 · NCT01042379
- CeralasertibPhase 2 · NCT04704661 · NCT04417062 · NCT04065269
- CetuximabPhase 2 · NCT07252739 · NCT07458347 · NCT07905924 · NCT07223047 · NCT07746141 · NCT06865664
- Checkpoint Inhibitor, ImmunePhase 2 · NCT04673942
- ChemotherapyPhase 2 · NCT06333314 · NCT06699472
- Chest RadiographyPhase 2 · NCT07539454 · NCT04751409
- CirtuvivintPhase 2 · NCT07032285
- CIV chemotherapyPhase 2 · NCT06816771
- CladribinePhase 2 · NCT03589729 · NCT04797767
- Clinical EncounterPhase 2 · NCT05969860
- CliniMACSPhase 2 · NCT02790515
- CobimetinibPhase 2 · NCT04079179 · NCT05691504
- Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)Phase 2 · NCT03778996
- Conservative treatmentPhase 2 · NCT06022159
- Cryoablation therapy + anti-PD-1 antibodyPhase 2 · NCT07602049
- Cyclophosphamide PillPhase 2 · NCT04388839
- CYT107Phase 2 · NCT07308886
- Dan222 + NiraparibPhase 2 · NCT01042379
- Daratumumab SCPhase 2 · NCT05907759
- DaraxonrasibPhase 2 · NCT07793253
- Datopotamab deruxtecanPhase 2 · NCT01042379
- Datopotamab deruxtecan + DurvalumabPhase 2 · NCT01042379
- Definitive radiotherapyPhase 2 · NCT07173972
- DexrazoxanePhase 2 · NCT01864109 · NCT01871766
- Dexrazoxane HydrochloridePhase 2 · NCT03589729 · NCT00077285
- DisulfiramPhase 2 · NCT05210374 · NCT07477457
- DostarlimabPhase 2 · NCT06521567 · NCT06333314
- Doxorubicin Hydrochloride Liposome+IrinotecanPhase 2 · NCT05457829
- Doxorubicin.Phase 2 · NCT03678883
- DT-7012Phase 2 · NCT07802652
- DurvalumabPhase 2 · NCT04521686 · NCT03660826 · NCT04065269 · NCT06008093 · NCT03851614 · NCT04668300
- Durvalumab plus OlaparibPhase 2 · NCT01042379
- EchocardiographyPhase 2 · NCT06571734
- EflornithinePhase 2 · NCT07321912
- EI or M-API regimen depending on patient agePhase 2 · NCT03643133
- ElacestrantPhase 2 · NCT07467772
- EnasidenibPhase 2 · NCT06176989
- Endoxifen + AbemaciclibPhase 2 · NCT01042379
- EnsartinibPhase 2 · NCT03155620 · NCT03213652
- EntrectinibPhase 2 · NCT02650401 · NCT02568267
- Envafolimab and neoadjuvant chemotherapyPhase 2 · NCT07142863
- Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)Phase 2 · NCT07243626
- EpacadostatPhase 2 · NCT03414229
- ErdafitinibPhase 2 · NCT03155620 · NCT03210714
- Ethiodized OilPhase 2 · NCT05672108
- EtrumadenantPhase 2 · NCT05886634
- EverolimusPhase 2 · NCT07619950 · NCT04185883 · NCT03114527
- Everolimus and LenvatinibPhase 2 · NCT07619950
- External Beam RadiotherapyPhase 2 · NCT06087861
- FAPI tracerPhase 2 · NCT07861217
- FDG-Positron Emission TomographyPhase 2 · NCT04339738
- FilgrastimPhase 2 · NCT06709495 · NCT07064018 · NCT00077285
- Filgrastim, peg-filgrastimPhase 2 · NCT06023641
- Fludarabine + Cyclophosphamide combinationPhase 2 · NCT03935893
- Fluorescence ImagingPhase 2 · NCT07650656
- Fluorescence-Guided SurgeryPhase 2 · NCT07650656
- FluzoparibPhase 2 · NCT05894018
- Follow-UpPhase 2 · NCT04751409
- G-CSFPhase 2 · NCT07602777 · NCT01864109 · NCT02790515
- GanetespibPhase 2 · NCT01042379
- GefitinibPhase 2 · NCT07477457
- Gem + DocPhase 2 · NCT07547592
- GemcitabinePhase 2 · NCT04383119 · NCT04999761 · NCT04521686 · NCT03598595 · NCT06498648 · NCT03093909 · NCT07223047 · NCT06840886 · NCT07144254 · NCT04577014 · NCT06308419
- Gemcitabine - 21 day cyclePhase 2 · NCT03678883
- Gemcitabine - 28 day cyclePhase 2 · NCT03678883
- GM-CSFPhase 2 · NCT02502786
- GSK 5733584Phase 2 · NCT01042379
- GSK 5733584 + DostarlimabPhase 2 · NCT01042379
- HFRT alonePhase 2 · NCT06476704
- High-dose MethotrexatePhase 2 · NCT07560826
- HPC,A InfusionPhase 2 · NCT02790515
- HS-20093Phase 2 · NCT06699576 · NCT05830123
- humanized anti-GD2 antibodyPhase 2 · NCT02502786
- Hypofractionated Radiation TherapyPhase 2 · NCT03819985 · NCT04562480 · NCT06022159 · NCT06905132
- Hypofractionated RadiotherapyPhase 2 · NCT03972930
- IdarubicinPhase 2 · NCT03589729
- image-guided radiotherapyPhase 2 · NCT00186992
- Imaging TechniquePhase 2 · NCT04751409
- INCMGA00012Phase 2 · NCT04968106 · NCT04438824
- Indocyanine GreenPhase 2 · NCT07650656
- Indocyanine green solution administered at 2.0mg/kg.Phase 2 · NCT04719156
- infusion of melphalan and dactinomycinPhase 2 · NCT04332874
- Intensity Modulated Radiation Therapy (IMRT)Phase 2 · NCT05301283
- Intensity-modulated radiation therapy (IMRT)Phase 2 · NCT04288375
- Interleukin-2Phase 2 · NCT04166006
- IpilimumabPhase 2 · NCT04416568 · NCT04551430 · NCT03138161 · NCT02834013 · NCT03307616 · NCT05836571 · NCT05407441 · NCT07444619 · NCT03449108
- IrinotecanPhase 2 · NCT04625907 · NCT07328425 · NCT01864109 · NCT01871766 · NCT04796012 · NCT06541262 · NCT03678883 · NCT05440786 · NCT03715933 · NCT07194044
- Irinotecan Combined with Temozolomide and Vincristine (VIT)Phase 2 · NCT07092306
- Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)Phase 2 · NCT07092306
- Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizumaPhase 2 · NCT07457775
- irinotecan liposome (II) + temozolomide + fluzoparibPhase 2 · NCT06827717
- Iscador*PPhase 2 · NCT05726383
- Isolated Limb InfusionPhase 2 · NCT04332874
- IvocizumabPhase 2 · NCT06683846
- IvonescimabPhase 2 · NCT07516925
- Ivonescimab (20mg/kg Q3W)Phase 2 · NCT01042379
- IvosidenibPhase 2 · NCT03155620 · NCT04195555
- Ixazomib CitratePhase 2 · NCT04305691
- KC1036Phase 2 · NCT06564272
- Larotrectinib SulfatePhase 2 · NCT03155620 · NCT03213704
- LasofoxifenePhase 2 · NCT01042379
- LenalidomidePhase 2 · NCT02523040
- LenvatinibPhase 2 · NCT04784247
- Lenvatinib mesylate capsulePhase 2 · NCT05617859
- Letetresgene autoleucel (lete-cel, GSK3377794)Phase 2 · NCT03967223
- LifileucelPhase 2 · NCT07741877
- Liposomal BupivacainePhase 2 · NCT04189783
- liposomal doxorubicinPhase 2 · NCT02659930 · NCT07817095 · NCT07194044
- Liposomal Doxorubicin (Doxil)Phase 2 · NCT05210374 · NCT06694324
- Liposomal IrinotecanPhase 2 · NCT07479732 · NCT06023641
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional AnlotinibPhase 2 · NCT07444918
- LobaplatinPhase 2 · NCT06714383
- loco-regional hyperthermiaPhase 2 · NCT04889742
- LomustinePhase 2 · NCT03678883
- low dose total body irradiationPhase 2 · NCT01804634
- LX-101Phase 2 · NCT07781891
- Lymph Node SamplingPhase 2 · NCT01871766
- Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation TherapyPhase 2 · NCT06436612
- MASCT-IPhase 2 · NCT06277154
- MelphalanPhase 2 · NCT02790515 · NCT01804634
- MESNAPhase 2 · NCT04897321 · NCT01864109 · NCT02790515 · NCT07428993
- metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapyPhase 2 · NCT06114225
- Metformin HydrochloridePhase 2 · NCT04758000
- Metformin Hydrochloride ERPhase 2 · NCT07291297
- MethioninePhase 2 · NCT00840047
- MifamurtidePhase 2 · NCT07787429 · NCT03643133
- MitomycinPhase 2 · NCT05672108
- Mitoxantrone Hydrochloride Liposome+Irinotecan+VincristinePhase 2 · NCT06514313
- MK-1084Phase 2 · NCT07252739
- MK-2206 with or without TrastuzumabPhase 2 · NCT01042379
- Moderately hypofractionated neoadjuvant radiotherapyPhase 2 · NCT07507773
- Moderately-Hypo-fractionation RadiotherapyPhase 2 · NCT04506008
- multi-kinase inhibitors in combination with bevacizumabPhase 2 · NCT06041490
- Mutation Carrier ScreeningPhase 2 · NCT03155620
- Myeloid Growth FactorPhase 2 · NCT01871766
- Nab paclitaxel.Phase 2 · NCT03678883
- NaxitamabPhase 2 · NCT05968768
- Negative Pressure Wound Therapy (NPWT) DressingsPhase 2 · NCT07048184
- Neoadjuvant RadiationPhase 2 · NCT06660810
- NeratinibPhase 2 · NCT01042379
- NiraparibPhase 2 · NCT05515575
- NirogacestatPhase 2 · NCT07539454
- Nivolumab IV Soln 100 MG/10MLPhase 2 · NCT03886311
- NKTR-214Phase 2 · NCT03282344
- No Intervention: Observational CohortPhase 2 · NCT04383119
- OlaparibPhase 2 · NCT03155620 · NCT03660826 · NCT04417062 · NCT04065269 · NCT03851614
- OleclumabPhase 2 · NCT04668300
- OMO-103Phase 2 · NCT06650514
- onfekafusp alfaPhase 2 · NCT04733183
- Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabPhase 2 · NCT01042379
- Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabPhase 2 · NCT01042379
- OST31-164Phase 2 · NCT04974008
- OVV-01，AK112Phase 2 · NCT07650838
- Paclitaxel Polymer Micelles + Gemcitabine + AnlotinibPhase 2 · NCT07359053
- Paclitaxel Polymer Micelles + Gemcitabine + LenvatinibPhase 2 · NCT07359053
- Paclitaxel.Phase 2 · NCT03678883
- PacritinibPhase 2 · NCT06052618
- PalbociclibPhase 2 · NCT06843967 · NCT03155620 · NCT06113809 · NCT05694871 · NCT04185883 · NCT04438824
- Patritumab and TrastuzumabPhase 2 · NCT01042379
- Pazopanib plus GemcitabinePhase 2 · NCT02203760
- Pembrolizumab - 4 cyclePhase 2 · NCT01042379
- Pembrolizumab - 8 cyclePhase 2 · NCT01042379
- Pembrolizumab, Eftilagimod alfaPhase 2 · NCT06128863
- pembrolizumab, pazopanibPhase 2 · NCT05679921
- PemetrexedPhase 2 · NCT07458347 · NCT06008093 · NCT03715933
- pemetrexed+cisplatinPhase 2 · NCT04605770
- PemigatinibPhase 2 · NCT06389799 · NCT06551896
- PenpulimabPhase 2 · NCT07612098
- Pertuzumab and TrastuzumabPhase 2 · NCT01042379
- Physician's ChoicePhase 2 · NCT06942442
- PirarubicinPhase 2 · NCT06714383
- PLX3397Phase 2 · NCT01042379
- PomalidomidePhase 2 · NCT04902443 · NCT04577755 · NCT02659930
- Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgeryPhase 2 · NCT03474094
- Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.Phase 2 · NCT03474094
- preoperativePhase 2 · NCT07169344
- Preoperative RadiotherapyPhase 2 · NCT07612098
- PropranololPhase 2 · NCT05797662 · NCT05961761
- Propranolol HydrochloridePhase 2 · NCT06445166
- Proton beam radiation or external beam radiation or brachytherapyPhase 2 · NCT06023641
- Proton Beam TherapyPhase 2 · NCT00496522
- PsilocybinPhase 2 · NCT06416085
- Psilocybin (high dose)Phase 2 · NCT07820033
- Psilocybin (low dose)Phase 2 · NCT07820033
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)Phase 2 · NCT06939855
- QL1706 + Eribulin + Anlotinib + RadiotherapyPhase 2 · NCT07205185
- Quadratus Lumborum BlockPhase 2 · NCT04189783
- RadiationPhase 2 · NCT01871766
- Radiation Therapy*Phase 2 · NCT01864109
- Radioactive particle implantationPhase 2 · NCT05894018
- Radionuclide ImagingPhase 2 · NCT03155620 · NCT03213704 · NCT04320888 · NCT03210714 · NCT03213652
- radiotherapyPhase 2 · NCT04625907 · NCT05839275 · NCT05950594 · NCT06835049 · NCT02275286 · NCT04599062 · NCT05774275 · NCT07578506
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)Phase 2 · NCT06126510
- Regorafenib 20MGPhase 2 · NCT04803877
- Regorafenib 40 MGPhase 2 · NCT04803877
- Rescue medicationPhase 2 · NCT07252739
- RetifanlimabPhase 2 · NCT06389799 · NCT04577014 · NCT06610682
- RibociclibPhase 2 · NCT03114527
- RiluzolePhase 2 · NCT06580002 · NCT07447050
- Rilvegostomig + TDXdPhase 2 · NCT01042379
- RituximabPhase 2 · NCT02790515
- RogaratinibPhase 2 · NCT04595747
- RucaparibPhase 2 · NCT04624178
- Sacituzumab tirumotecan (sac-TMT)Phase 2 · NCT07252739
- SamotolisibPhase 2 · NCT03155620
- Sarilumab + Cemiplimab + PaclitaxelPhase 2 · NCT01042379
- SBRTPhase 2 · NCT03548428
- SD-101 + PembrolizumabPhase 2 · NCT01042379
- SelinexorPhase 2 · NCT05985161 · NCT06239272 · NCT05333458
- SelpercatinibPhase 2 · NCT03155620 · NCT03899792 · NCT04320888
- Selumetinib + ZEN-3694 ± DurvalumabPhase 2 · NCT05253131
- Selumetinib SulfatePhase 2 · NCT03155620
- SFRTPhase 2 · NCT07501026
- SGN-LIV1APhase 2 · NCT01042379
- SigniforPhase 2 · NCT06456359
- SirolimusPhase 2 · NCT02574728 · NCT02790515 · NCT07725380
- SJCARB7H3_41BBL infusionPhase 2 · NCT07428993
- Skin BiopsyPhase 2 · NCT07539454
- SorafenibPhase 2 · NCT01871766 · NCT07787429
- SpartalizumabPhase 2 · NCT04802876
- Spatially Fractionated Radiation Therapy Combined with Toripalimab and Human Granulocyte-Macrophage Colony-Stimulating Factor for InjectionPhase 2 · NCT07342322
- Standard Absorbent DressingsPhase 2 · NCT07048184
- Standard ChemotherapyPhase 2 · NCT07646080
- Standard TherapyPhase 2 · NCT01042379
- Stereotactic body radiotherapy (SBRT)Phase 2 · NCT07817095
- Stryker SPY-PHI Imaging DevicePhase 2 · NCT04719156
- SunitinibPhase 2 · NCT03900793 · NCT07477457
- Surgical ResectionPhase 2 · NCT01871766 · NCT06023641 · NCT06239272 · NCT06492954
- SurufatinibPhase 2 · NCT05839275 · NCT05106777
- Surufatinib + envafolimabPhase 2 · NCT05722977
- SYD985 ([vic-]trastuzumab duocarmazine)Phase 2 · NCT01042379
- T-DM1 and PertuzumabPhase 2 · NCT01042379
- TabelecleucelPhase 2 · NCT04554914
- TacrolimusPhase 2 · NCT02790515 · NCT01804634
- Talazoparib plus IrinotecanPhase 2 · NCT01042379
- Talimogene LaherparepvecPhase 2 · NCT04599062 · NCT02923778 · NCT06660810
- Talimogene Laherparepvec (T-VEC)Phase 2 · NCT03069378
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]Phase 2 · NCT03886311
- TazemetostatPhase 2 · NCT03155620 · NCT04917042 · NCT05407441
- TebentafuspPhase 2 · NCT06942442
- TemozolomidePhase 2 · NCT04625907 · NCT01864109 · NCT04200443 · NCT06709495 · NCT04796012 · NCT06023641 · NCT04901702 · NCT06541262 · NCT05440786 · NCT03715933 · NCT07194044 · NCT04337177
- Temozolomide+Irinotecan+VincristinePhase 2 · NCT06514313 · NCT05457829
- TGI chemotherapyPhase 2 · NCT06816771
- Thermal Ablation TherapyPhase 2 · NCT02713269
- ThiotepaPhase 2 · NCT02790515
- Tigilanol TiglatePhase 2 · NCT05755113
- TipifarnibPhase 2 · NCT03155620 · NCT04284774
- TirzepatidePhase 2 · NCT07874828
- Tislelizumab+liposomal doxorubicin+ifosfamidePhase 2 · NCT06849986
- TopotecanPhase 2 · NCT06840886 · NCT07321912 · NCT07194044
- ToripalimabPhase 2 · NCT07646080 · NCT04785196 · NCT07817095
- Toripalimab Combined With CAV/IE chemotherapyPhase 2 · NCT04589741
- TQB2916 injection + doxorubicin hydrochloride for injectionPhase 2 · NCT06500091
- TQB2916 injection+penpulimab injectionPhase 2 · NCT06500091
- Trabectedin 0.25 MG/1 VIAL Intravenous Powder for SolutionPhase 2 · NCT03886311
- TrametinibPhase 2 · NCT07477457 · NCT04185883
- Transarterial ChemoembolizationPhase 2 · NCT05672108
- Trastuzumab DeruxtecanPhase 2 · NCT04704661 · NCT06840886 · NCT04616560
- Treatment by regorafenib and best supportive carePhase 2 · NCT04698785
- TremelimumabPhase 2 · NCT06008093
- TrilaciclibPhase 2 · NCT06714383
- Trilaciclib Injection [Cosela]Phase 2 · NCT06699472
- Trilaciclib with or without trastuzumab + pertuzumabPhase 2 · NCT01042379
- Tris-acryl Gelatin MicrospheresPhase 2 · NCT05672108
- Tucatinib plus trastuzumab and pertuzumabPhase 2 · NCT01042379
- Tumor Infiltrating Lymphocytes (TIL)Phase 2 · NCT03935893
- UbamatamabPhase 2 · NCT06444880
- UlixertinibPhase 2 · NCT03698994 · NCT03155620
- Ultra-Hypo-fractionation RadiotherapyPhase 2 · NCT04506008
- UTD2 + tislelizumab + doxorubicinPhase 2 · NCT07842276
- VAM_GROUPPhase 2 · NCT07028086
- VebreltinibPhase 2 · NCT07153887
- VemurafenibPhase 2 · NCT03155620
- VismodegibPhase 2 · NCT01267955
- Vusolimogene Oderparepvec (VO)Phase 2 · NCT06898970
- VV1 + CemiplimabPhase 2 · NCT01042379
- WAP-IMRTPhase 2 · NCT04022213
- Z-endoxifenPhase 2 · NCT01042379
- ZalifrelimabPhase 2 · NCT04028063
- ZanidatamabPhase 2 · NCT07192068 · NCT01042379
- ZanzalintinibPhase 2 · NCT07193550 · NCT07283731 · NCT07773454 · NCT06571734 · NCT06957431
- ZimberelimabPhase 2 · NCT05886634
- [203Pb]Pb-PSV359Phase 1/2 · NCT06710756
- [212Pb]Pb-PSV359Phase 1/2 · NCT06710756
- 1.0% IP-001 for InjectionPhase 1/2 · NCT05688280
- 177Lu-BetaBartPhase 1/2 · NCT07189871
- 64Cu-LNTH-1363SPhase 1/2 · NCT06298916
- a targeted probe B7H3-IRDye800CWPhase 1/2 · NCT06778603
- Aerosolized AldesleukinPhase 1/2 · NCT01590069
- Afamitresgene autoleucelPhase 1/2 · NCT05642455
- AFNT-211Phase 1/2 · NCT06105021
- AL58805Phase 1/2 · NCT07811232 · NCT07811297
- AL8326Phase 1/2 · NCT07811232
- AMXT 1501 DicapratePhase 1/2 · NCT06465199
- ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)Phase 1/2 · NCT07145450
- ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)Phase 1/2 · NCT07145450
- ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)Phase 1/2 · NCT07145450
- Anti-PD-1 monoclonal antibodyPhase 1/2 · NCT05774275
- Antibody-drug conjugate (ADC)Phase 1/2 · NCT06797999
- Apatinib in arm1Phase 1/2 · NCT07479732
- APG-115Phase 1/2 · NCT06735820 · NCT04785196
- Archive Sample RetrievalPhase 1/2 · NCT07830667
- BetaBart + unlabeled BetaBartPhase 1/2 · NCT07189871
- bexmarilimabPhase 1/2 · NCT07460986
- BLU-924Phase 1/2 · NCT07629960
- BMS-986504Phase 1/2 · NCT07549022
- BMS-986523Phase 1/2 · NCT07223047
- BNCTPhase 1/2 · NCT06603987
- CAR-GPC3 T CellsPhase 1/2 · NCT05120271
- CART therapyPhase 1/2 · NCT06836505
- CCNUPhase 1/2 · NCT07811297
- CD146/HER2 CAR-T cellsPhase 1/2 · NCT07066982
- CobolimabPhase 1/2 · NCT06521567
- CYCLOPHOSPHAMIDE and FLUDARABINPhase 1/2 · NCT05296564
- DecitabinePhase 1/2 · NCT02650986
- DFMOPhase 1/2 · NCT06892678
- Dinutuximab beta, Sirolimus and IrinotecanPhase 1/2 · NCT07853105
- DomatinostatPhase 1/2 · NCT07725380
- Dual X-ray AbsorptiometryPhase 1/2 · NCT04851119
- EBNK-001 + IL-15 + PembrolizumabPhase 1/2 · NCT07410676
- Eflornithine (DFMO)Phase 1/2 · NCT06465199
- ELI-002 7PPhase 1/2 · NCT05726864
- ElimusertibPhase 1/2 · NCT05071209
- EnzalutamidePhase 1/2 · NCT04557449
- FulvestrantPhase 1/2 · NCT07811232 · NCT04557449
- GD2-CART01Phase 1/2 · NCT03373097
- GEM/DOX + TGFBi expanded NK cellsPhase 1/2 · NCT05634369
- GI-102Phase 1/2 · NCT05824975
- GI-102 subcutaneous (SC)Phase 1/2 · NCT05824975
- GiredestrantPhase 1/2 · NCT04557449
- GPC3 CD146 CAR-T cellsPhase 1/2 · NCT07067255
- HBI 0201-ESO TCRTPhase 1/2 · NCT05296564
- HDM201Phase 1/2 · NCT05180695
- HH2853 TabletsPhase 1/2 · NCT04390737
- HTL0039732 CapsulesPhase 1/2 · NCT05944237
- HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusionPhase 1/2 · NCT05944237
- HydroxychloroquinePhase 1/2 · NCT03598595
- IG IMRTPhase 1/2 · NCT01659203
- IG-IMPTPhase 1/2 · NCT01659203
- ipilimumab +pembrolizumab +durvalumabPhase 1/2 · NCT05187338
- Isolated Chemotherapeutic Lung PerfusionPhase 1/2 · NCT03965234
- IsophosphamidePhase 1/2 · NCT05590572
- LB-100 plus DoxorrubicinPhase 1/2 · NCT05809830
- LetrozolePhase 1/2 · NCT04557449
- LeukapheresisPhase 1/2 · NCT07261657 · NCT02650986 · NCT07227571
- LNTH2403 Phase 1 dosePhase 1/2 · NCT07357519
- M7824Phase 1/2 · NCT04303117
- MetastasectomyPhase 1/2 · NCT03965234
- Miltenyi CliniMACS Prodigy ® systemPhase 1/2 · NCT06625190
- MirdametinibPhase 1/2 · NCT06843967
- MT-4561Phase 1/2 · NCT06943521
- Multiple sarcoma-specific CAR-T cells and sarcoma vaccinesPhase 1/2 · NCT04433221
- nab-PaclitaxelPhase 1/2 · NCT04999761 · NCT07223047
- Neoantigen Peptide VaccinePhase 1/2 · NCT05269381
- Nivolumab InjectionPhase 1/2 · NCT04165330
- Olaparib; 177Lu-DOTATATEPhase 1/2 · NCT06607692
- ONC-392Phase 1/2 · NCT04140526
- OnivydePhase 1/2 · NCT04901702
- ONO-4538HSCPhase 1/2 · NCT07734116
- Oral repotrectinib (TPX-0005)Phase 1/2 · NCT03093116 · NCT04094610
- PDS01ADCPhase 1/2 · NCT04303117
- PEEL-224Phase 1/2 · NCT06709495 · NCT06721689
- PegfilgrastimPhase 1/2 · NCT06709495 · NCT07064018
- Peptide vaccine IPXPhase 1/2 · NCT06094101
- PF-07220060Phase 1/2 · NCT04557449
- pH Low Insertion Peptide-exatecan Conjugate CBX-12Phase 1/2 · NCT07830667
- Phase 1b: APG-115+pembrolizumabPhase 1/2 · NCT03611868
- Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).Phase 1/2 · NCT07357519
- PM14Phase 1/2 · NCT05146440
- Proton beam radiation therapyPhase 1/2 · NCT06239272
- PucotenlimabPhase 1/2 · NCT06456892
- Radiologic Imaging ProcedurePhase 1/2 · NCT07830667
- Recombinant Granulocyte Colony-Stimulating FactorPhase 1/2 · NCT04797767
- RegorafenibPhase 1/2 · NCT04625907
- Ris-RezPhase 1/2 · NCT07602777
- RNK08954-01Phase 1/2 · NCT06667544
- SA53-OS (phase 1)Phase 1/2 · NCT06578624
- SA53-OS (phase 2)Phase 1/2 · NCT06578624
- Sarcoma-specific CAR-T cellsPhase 1/2 · NCT03356782
- SargramostimPhase 1/2 · NCT05269381
- SilmitasertibPhase 1/2 · NCT06541262
- SintilimabPhase 1/2 · NCT05839275
- SOT106Phase 1/2 · NCT07801222
- Spatially-fractionated Radiation TherapyPhase 1/2 · NCT06327477
- Spedox-6Phase 1/2 · NCT07064018
- STC-15 in combination with toripalimabPhase 1/2 · NCT06975293
- STC-15 monotherapyPhase 1/2 · NCT06975293
- SulfatinibPhase 1/2 · NCT05590572
- T3011Phase 1/2 · NCT04370587
- T3011 + pembrolizumabPhase 1/2 · NCT04370587
- TalazoparibPhase 1/2 · NCT04901702
- TamoxifenPhase 1/2 · NCT04557449
- TegavivintPhase 1/2 · NCT04851119 · NCT07144254
- Temozolomide (TMZ)Phase 1/2 · NCT06721689 · NCT07811297
- TGFbDNRII-transduced Autologous Tumor Infiltrating LymphocytesPhase 1/2 · NCT02650986
- TiragolumabPhase 1/2 · NCT05286801
- TivozanibPhase 1/2 · NCT05000294
- TNG462Phase 1/2 · NCT05732831
- trastuzumab deruxtecan (T-DXd)Phase 1/2 · NCT05824975
- VactosertibPhase 1/2 · NCT05588648
- VenetoclaxPhase 1/2 · NCT05735184 · NCT07713732 · NCT04797767
- Zilovertamab vedotinPhase 1/2 · NCT06395103
- [Ac 225]RTX-2358Phase 1 · NCT07156565
- 177Lu-DFC413Phase 1 · NCT07261631
- 21.15.GPC3-CAR T cellsPhase 1 · NCT06198296
- 68Ga-DFC413Phase 1 · NCT07630961
- 68Ga-NNS309Phase 1 · NCT07261631 · NCT07630961
- 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)Phase 1 · NCT06537596
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid TumorsPhase 1 · NCT06508307
- AB122Phase 1 · NCT04999761
- AB154Phase 1 · NCT04999761
- ActinomycinPhase 1 · NCT07194044
- AdebrelimabPhase 1 · NCT06699576
- Administration of CC-3Phase 1 · NCT05999396
- AfatinibPhase 1 · NCT04185883
- AGAR T cellsPhase 1 · NCT04377932
- AGX101Phase 1 · NCT06440005
- AMG 404Phase 1 · NCT04185883
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140Phase 1 · NCT04616248
- attIL2-T cellsPhase 1 · NCT05621668
- Autologous CAR Positive T cellsPhase 1 · NCT00902044
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiationPhase 1 · NCT03132922
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cellsPhase 1 · NCT03132922
- Autologous HER2-specific T cellsPhase 1 · NCT00902044
- AVA6000Phase 1 · NCT04969835
- Axl/Mer/CSF1R Inhibitor Q702Phase 1 · NCT06712810
- AzacitidinePhase 1 · NCT05735184 · NCT03628209
- B7-H3 CAR T cellsPhase 1 · NCT04897321
- B7-H3-CAR T CellsPhase 1 · NCT07222735
- B7-H3CART Dose (Intravenous)Phase 1 · NCT06500819
- Becotatug VedotinPhase 1 · NCT07584499
- Bevacizumab (Avastin)Phase 1 · NCT07897968
- BG-85738Phase 1 · NCT07746141
- BI 1701963Phase 1 · NCT04185883
- Biological/Vaccine: hBRCA84D CAR T cellsPhase 1 · NCT07751380
- BOLD-100Phase 1 · NCT07027423
- BTX-A51Phase 1 · NCT06414434
- C7R-GD2.CART cellsPhase 1 · NCT03635632
- Carboplatin, pemetrexed, docetaxel, paclitaxelPhase 1 · NCT04185883
- CARE T cellsPhase 1 · NCT04715191
- CATCH T cellsPhase 1 · NCT05103631
- Chimeric Antigen Receptor (CAR) Therapy InfusionPhase 1 · NCT07897968
- CLR 131Phase 1 · NCT03478462
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)Phase 1 · NCT07139990
- Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)Phase 1 · NCT07139990
- Cohort C: Sarcoma Pre-Operative PULSARPhase 1 · NCT07139990
- Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbRPhase 1 · NCT07139990
- Copper GluconatePhase 1 · NCT05210374
- CRD3874Phase 1 · NCT06021626
- CytaluxPhase 1 · NCT06235125
- DaunorubicinPhase 1 · NCT05735184
- Definitive Surgical ResectionPhase 1 · NCT04420975
- DEG6498Phase 1 · NCT07244835
- Dinutuximab betaPhase 1 · NCT06839703
- Dostarlimab in Combination Antiretroviral TherapyPhase 1 · NCT05646082
- Doxorubicin 75 mg/m^2Phase 1 · NCT07027423
- DS-2243aPhase 1 · NCT06644755
- DXC008Phase 1 · NCT06926283
- EntinostatPhase 1 · NCT07888114
- EpirubicinPhase 1 · NCT06699576
- Eribulin MesylatePhase 1 · NCT03361436
- EWSR1 immunotherapyPhase 1 · NCT07695311
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and ZoledronatePhase 1 · NCT05400603
- FF-10850 Topotecan Liposome InjectionPhase 1 · NCT04047251
- FGFR4-CAR T CellsPhase 1 · NCT06865664
- FH FOLR1 ST CAR T-cellsPhase 1 · NCT07227571
- Fludarabine phosphatePhase 1 · NCT06083883
- FluorouracilPhase 1 · NCT04999761 · NCT03715933
- FOLFIRIPhase 1 · NCT07458347 · NCT06840886
- FOLFOXPhase 1 · NCT06840886
- Functional Precision MedicinePhase 1 · NCT05857969
- Gallium Ga 68 FAPi-46Phase 1 · NCT04457258 · NCT07118176
- GCAR1Phase 1 · NCT07104682 · NCT06789081 · NCT06813417 · NCT07297667
- GD2 T cellsPhase 1 · NCT01953900
- Gemcitabine/nab-paclitaxelPhase 1 · NCT07458347
- Glutaminase-1 Inhibitor IACS-6274Phase 1 · NCT05039801
- H2 Receptor AntagonistPhase 1 · NCT06789172
- HFB200301Phase 1 · NCT05238883
- Hypofractionationed Radiation TherapyPhase 1 · NCT06812052
- i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cellsPhase 1 · NCT07211737
- iC9.GD2.CAR.IL-15 T-cellsPhase 1 · NCT03721068
- ICG administrationPhase 1 · NCT06610071
- IDOV-Immune (oncolytic vaccinia virus)Phase 1 · NCT06910657
- IMA203Phase 1 · NCT06946225
- INBRX-109Phase 1 · NCT03715933
- Irinotecan Hydrochloride Liposome InjectionPhase 1 · NCT06340204
- IV Chemotherapy (Regimen 1)Phase 1 · NCT04185883
- IV Chemotherapy (Regimen 2)Phase 1 · NCT04185883
- KIVU-107Phase 1 · NCT07229313
- KST-6051Phase 1 · NCT07458347
- KXV01 TCR Lentinvivo InjectionPhase 1 · NCT07596693
- LeucovorinPhase 1 · NCT03715933
- Lifileucel (LN-144/LN-145)Phase 1 · NCT05607095
- LosartanPhase 1 · NCT03900793
- Low-dose irradiationPhase 1 · NCT06889766
- LP-284Phase 1 · NCT06132503
- Lutetium Lu 177-EdotreotidePhase 1 · NCT06441331
- LVGN3616 + LVGN6051 + Bevacizumab + CyclophosphamidePhase 1 · NCT05075993
- LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + CyclophosphamidePhase 1 · NCT05075993
- LVGN3616 + LVGN6051 + LVGN7409 + Nab-PaclitaxelPhase 1 · NCT05075993
- LVGN3616 + LVGN6051 + Nab-PaclitaxelPhase 1 · NCT05075993
- LY3410738Phase 1 · NCT04521686
- LymphodepletionPhase 1 · NCT06748872
- M3554Phase 1 · NCT06641908
- MetarrestinPhase 1 · NCT04222413
- mFOLFIRINOXPhase 1 · NCT07905924
- mFOLFOX6Phase 1 · NCT07458347
- MGC026 Dose EscalationPhase 1 · NCT06242470
- MGC026 Dose for ExpansionPhase 1 · NCT06242470
- Mirvetuximab SoravtansinePhase 1 · NCT06840886
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamidePhase 1 · NCT02013336
- MocetinostatPhase 1 · NCT04299113
- Modified Vaccinia Virus Ankara Vaccine Expressing p53Phase 1 · NCT02432963
- MQ719Phase 1 · NCT05859074
- mRNA-4203Phase 1 · NCT06946225
- MRTX1719Phase 1 · NCT05245500
- MVASI® (bevacizumab-awwb)Phase 1 · NCT04185883
- Nab-SirolimusPhase 1 · NCT06308419
- Nanoplexed Poly I:C BO-112Phase 1 · NCT04420975
- Neoantigen vaccine + anti-PD1 antibodyPhase 1 · NCT07648069
- Neoantigen vaccine + specific lymphocytes + anti-PD1 antibodyPhase 1 · NCT07648069
- Nivolumab Injectable ProductPhase 1 · NCT04995003
- Non-myeloablative lymphodepleting chemotherapyPhase 1 · NCT06889766
- NY-ESO-1 TCR redirected autologous T cell productPhase 1 · NCT06889766
- NY-ESO-1 TCR/IL-15 NKPhase 1 · NCT06083883
- OKN4395Phase 1 · NCT06789172
- ONC201Phase 1 · NCT05542407
- PanitumumabPhase 1 · NCT04185883
- PCNA Inhibitor AOH1996Phase 1 · NCT05227326
- Pegylated Liposomal Doxorubicin HydrochloridePhase 1 · NCT05711615
- PelcitoclaxPhase 1 · NCT05691504
- Pembrolizumab Injectable ProductPhase 1 · NCT04995003
- PembrollizumabPhase 1 · NCT06242470
- PeposertibPhase 1 · NCT05711615
- PeptiCRAd-1Phase 1 · NCT05492682
- PHST001Phase 1 · NCT06840886
- Poly ICLCPhase 1 · NCT04616248
- Post Treatment SurgeryPhase 1 · NCT03628209
- QuizartinibPhase 1 · NCT05735184
- RamucirumabPhase 1 · NCT04999761
- REC617Phase 1 · NCT07633756
- Recombinant Flt3 LigandPhase 1 · NCT04616248
- regorafenib tabletPhase 1 · NCT05830084
- RMC-4630Phase 1 · NCT04185883
- RO7673396Phase 1 · NCT06884618
- RO7836748Phase 1 · NCT07905924
- SC-CAR.GPC3xIL15.21 CAR T cellsPhase 1 · NCT07148050 · NCT07224568
- SCRI-E2CAR_EGFRtv1Phase 1 · NCT05312411
- second generation 4-1BBζ B7H3-EGFRt-DHFRPhase 1 · NCT04483778
- second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGPhase 1 · NCT04483778
- second generation 4-1BBζ EGFR806-EGFRtPhase 1 · NCT03618381
- second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tGPhase 1 · NCT03618381
- Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cellsPhase 1 · NCT07172958
- SHY-ONC6Phase 1 · NCT07705334
- SON-1010Phase 1 · NCT05352750
- SotorasibPhase 1 · NCT04185883
- ST-01156Phase 1 · NCT07197554
- Stereotactic Body Radiation Therapy (SBRT)Phase 1 · NCT06492954
- STI-1386Phase 1 · NCT05361954
- Super1 TCR-TPhase 1 · NCT06942143
- T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell TherapyPhase 1 · NCT06474676
- T cells or CAR T cellsPhase 1 · NCT04995003
- Ta-NPs (10% Tumor Volume)Phase 1 · NCT07578506
- Ta-NPs (2% Tumor Volume)Phase 1 · NCT07578506
- Ta-NPs (5% Tumor Volume)Phase 1 · NCT07578506
- TAS-102Phase 1 · NCT04999761
- TAS-115Phase 1 · NCT04999761
- TAS-116Phase 1 · NCT04999761
- TAS-120Phase 1 · NCT04999761
- TCR-T cells (MDG1015)Phase 1 · NCT06748872
- TCRαβ+/CD19+ depleted Haploidentical HSCTPhase 1 · NCT02508038
- Therapeutic Conventional SurgeryPhase 1 · NCT03361436
- TLN-499Phase 1 · NCT07713732
- TNO155Phase 1 · NCT04185883
- TocilizumabPhase 1 · NCT04616248
- Trifluridine + TipiracilPhase 1 · NCT03715933
- TURALIO(R)Phase 1 · NCT02390752
- UB_TT170Phase 1 · NCT05312411
- VAC/VTC chemotherapyPhase 1 · NCT07888114
- VAL-413Phase 1 · NCT04337177
- vobramitamab tavatecanPhase 1 · NCT06242470
- VorinostatPhase 1 · NCT04308330
- VZV vaccinePhase 1 · NCT01953900
- X-PACTPhase 1 · NCT04389281
- XaluritamigPhase 1 · NCT07297979
- XS-02 capsulesPhase 1 · NCT06531486
- ZI-MA4-1 (TCR-NK cells)Phase 1 · NCT07613723
- ZiftomenibPhase 1 · NCT05735184
- Ziv-AfliberceptPhase 1 · NCT02298959
- ZL-6201Phase 1 · NCT07374848
- ZoledronatePhase 1 · NCT02508038
- 18F-FDGEarly phase 1 · NCT04457258
- 5-ALAEarly phase 1 · NCT07038278
- 89Zr-DFO-N-Suc-C9scFvEarly phase 1 · NCT06645808
- 89Zr-DFO-N-Suc-F8scFvEarly phase 1 · NCT06645808
- AscorbateEarly phase 1 · NCT04634227
- AZD9592Early phase 1 · NCT04541108
- AZD9592 + PembrolizumabEarly phase 1 · NCT04541108
- AZD9592 + RilvegostomigEarly phase 1 · NCT04541108
- AZD9592 + SabestomigEarly phase 1 · NCT04541108
- AZD9592 + VolrustomigEarly phase 1 · NCT04541108
- DefinityEarly phase 1 · NCT07436364
- ICG INFUSION 5MG/KGEarly phase 1 · NCT07658768
- ICI TherapyEarly phase 1 · NCT07389525
- INN805Early phase 1 · NCT07459283
- irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylatorEarly phase 1 · NCT01189643
- Montelukast 10 Mg Oral TabletEarly phase 1 · NCT06887673
- Montelukast 10 Mg Oral Tablet and SPM 4 gEarly phase 1 · NCT06887673
- Nogapendekin Alfa InbakiceptEarly phase 1 · NCT07261657
- PBA-0111Early phase 1 · NCT06700070
- personalized neoantigen mRNA vaccineEarly phase 1 · NCT06932861
- PET/CT scanEarly phase 1 · NCT06645808
- PlixorafenibEarly phase 1 · NCT06610682
- RilvegostomigEarly phase 1 · NCT04541108
- Romiplostim (AMG-531)Early phase 1 · NCT07048249
- SabestomigEarly phase 1 · NCT04541108
- TCR-T cellsEarly phase 1 · NCT07342738
- VolrustomigEarly phase 1 · NCT04541108
Closest to patients
- Combined Chemotherapy With or Without Zoledronic Acid for Patients With OsteosarcomaCombined Chemotherapy With or Without Zoledronic Acid for Patients With OsteosarcomaCentre Henri Becquerel · Rouen, France + 46 more hospitalsPhase 3Primary completion 2015
- Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCAssess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCResearch Site · Woodville South, Australia + 158 more hospitalsPhase 3Primary completion 2016
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaCombination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaUMC Cancer Center / UMC Health System · Lubbock, United States + 313 more hospitalsPhase 3Primary completion 2021
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Bioglass-Doped Hydroxyapatite Sol-Gel Coatings Enhance Curcumin Release and Biological Performance of Ti6Al4V Orthopedic Implants.
Bioglass-Doped Hydroxyapatite Sol-Gel Coatings Enhance Curcumin Release and Biological Performance of Ti6Al4V Orthopedic Implants.
ACS applied bio materials
PubMed · PMID 42875177Publication
3D-printed tricalcium phosphate scaffolds with Quercetin-zinc chelation for osteogenic, antibacterial and anti-osteosarcoma activity.
3D-printed tricalcium phosphate scaffolds with Quercetin-zinc chelation for osteogenic, antibacterial and anti-osteosarcoma activity.
Regenerative biomaterials
PubMed · PMID 42894702Case report
CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report.
CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report.
Case reports in oncology
PubMed · PMID 42924048Publication
Cannabidiol selectively downregulates FAM111B expression and induces apoptosis in fibrosarcoma cells: an in vitro study.
Cannabidiol selectively downregulates FAM111B expression and induces apoptosis in fibrosarcoma cells: an in vitro study.
Journal of cannabis research
PubMed · PMID 42958469
Find fellow researchers
Groups with active Sarcoma work.
Memorial Sloan Kettering Cancer Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
National Cancer Institute
Bethesda, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Stanford University
Stanford, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Centre Léon Bérard
Lyon, France
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Institut Gustave Roussy
Villejuif, France
Team details appear once the team leader joins.
Is this your team? Claim it